In RA, levels of proinflammatory mediators (MMP-3, IL-6, IFN-γ, and TNF-α) correlate with CHI3L1, and anti-rheumatic factor therapy reduces CHI3L1 levels in patients193–196. Here, CHI3L1 is linked to rheumatoid arthritis.